CSL (AU:CSL)
ASX:CSL
Want to see AU:CSL full AI Analyst Report?
CSL Stock Chart & Stats
AU$137.13
-AU$0.78(-0.27%)
At close: 4:00 PM EST
AU$137.13
-AU$0.78(-0.27%)
Day’s Range― - ―
52-Week RangeAU$122.48 - AU$275.79
Previous CloseN/A
Volume375.76K
Average Volume (3M)974.43K
Market Cap
AU$59.67B
Enterprise ValueAU$55.77B
Total Cash (Recent Filing)AU$1.15B
Total Debt (Recent Filing)AU$12.58B
Price to Earnings (P/E)34.1
Beta0.55
Next Earnings
Aug 18, 2026EPS Estimate
3.96Next Dividend Ex-DateN/A
Dividend Yield2.58%
Share Statistics
EPS (TTM)2.98
Shares Outstanding485,318,970
10 Day Avg. Volume1,091,561
30 Day Avg. Volume974,433
Financial Highlights & Ratios
PEG Ratio1.90
Price to Book (P/B)3.94
Price to Sales (P/S)4.94
P/FCF Ratio29.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$200.30Price Target Upside46.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)6.88
Revenue Forecast (FY)AU$15.80B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationCSL exhibits durable cash generation: free cash flow grew 25.2% and operating cash flow converts to income at a 1.19x rate. Strong cash conversion funds R&D, supports buybacks and dividends, and provides flexibility to absorb cyclical vaccine seasonality or fund restructuring without immediate capital markets reliance.
High Margins And Operating EfficiencyCSL's sustained high gross and EBITDA margins reflect specialized plasma-derived therapies and differentiated vaccine products. Healthy margins support reinvestment in manufacturing and pipeline work, provide a buffer against seasonal vaccine volatility, and underpin long-term cash generation even if top-line growth moderates.
Integrated Plasma Platform & Product MomentumCSL's vertically integrated plasma supply and manufacturing, paired with successful new launches (HEMGENIX, ANDEMBRY), creates durable competitive advantage. Converting owned plasma into premium therapies and rapid uptake of new products supports sustainable revenue diversification and reduces sole reliance on seasonal vaccine cycles.
Bears Say
Large Non‑cash ImpairmentsMaterial impairments (~$1.1bn after tax) reflect write-downs of prior investments and licensing assets. While largely non‑cash, they reduce reported equity and highlight portfolio execution and valuation risks, raising uncertainty about return profiles and management's prior capital allocation decisions over the medium term.
Slowing Revenue Growth And H2 Execution DependenceRevenue growth has moderated (≈3% latest year) and H1 fell 4% cc, with management forecasting recovery in H2 for Ig and China albumin. This creates a structural execution risk: sustained top‑line growth depends on operational recoveries and tender/reimbursement timing rather than purely organic demand expansion.
Policy And Reimbursement Headwinds (Ig)Medicare Part D reforms and contract expirations materially pressured Ig sales in H1. Policy-driven reimbursement changes and contract cycles are durable structural risks for specialty biologics revenues, potentially compressing volumes and pricing in key markets absent sustained product differentiation or new reimbursement pathways.
CSL News
CSL FAQ
What was CSL’s price range in the past 12 months?
CSL lowest share price was AU$122.48 and its highest was AU$275.79 in the past 12 months.
What is CSL’s market cap?
CSL’s market cap is AU$59.67B.
When is CSL’s upcoming earnings report date?
CSL’s upcoming earnings report date is Aug 18, 2026 which is in 103 days.
How were CSL’s earnings last quarter?
CSL released its earnings results on Feb 10, 2026. The company reported AU$5.693 earnings per share for the quarter, missing the consensus estimate of AU$5.848 by -AU$0.155.
Is CSL overvalued?
According to Wall Street analysts CSL’s price is currently Undervalued.
Does CSL pay dividends?
CSL pays a Semiannually dividend of AU$2.451 which represents an annual dividend yield of 2.58%. See more information on CSL dividends here
What is CSL’s EPS estimate?
CSL’s EPS estimate is 3.96.
How many shares outstanding does CSL have?
CSL has 485,318,970 shares outstanding.
What happened to CSL’s price movement after its last earnings report?
CSL reported an EPS of AU$5.693 in its last earnings report, missing expectations of AU$5.848. Following the earnings report the stock price went down -4.638%.
Which hedge fund is a major shareholder of CSL?
Currently, no hedge funds are holding shares in AU:CSL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CSL Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$200.30 (46.07% Upside)
AU$200.30 (46.07% Upside)
Blogger Sentiment
Bullish
AU:CSL Sentiment 84%
Sector Average 72%
Sector Average 72%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.80%
12-Months-Change
Fundamentals
Return on Equity
7.56%
Trailing 12-Months
Asset Growth
-1.42%
Trailing 12-Months
Company Description
CSL
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The CSL Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
CSL Company Deck
CSL Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a balanced picture: operational strengths (strong cash generation, share buyback expansion, cost-savings progress, solid Vifor performance, successful new product launches and Seqirus commercial gains) are offset by meaningful near-term pressures (H1 revenue decline, major non-cash impairments and one-off restructuring costs, policy-driven weakness in albumin and Ig headwinds, iron generics and KCENTRA competitive pricing). Management emphasizes these impairments are largely non‑cash, that the transformation is delivering tangible savings, and they have maintained full-year guidance while laying out remediation steps for weaker areas. The tone is cautiously constructive but with material near-term risks that require execution in H2 to validate the outlook.View all AU:CSL earnings summariesCSL Stock 12 Month Forecast
Average Price Target
AU$200.30
▲(46.07% Upside)
Technical Analysis
Opthea
―
Mesoblast Limited
―
Starpharma Holdings Limited
―
Telix Pharmaceuticals
―
Clarity Pharmaceuticals Ltd.
―
Options Prices
Currently, No data available
---